FierceBiotech3d
JPM25: GSK’s CSO shares science strategy behind deal-heavy year
And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...
Goodwin Enlisted for $1.15 Billion GSK Acquisition of US Biopharma Business
A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical ...
FierceBiotech5d
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...
FiercePharma3d
JPM25: GSK, Sanofi CEOs welcome 'transparency' in response to anti-vaccine movement in US
The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...
BioSpace4d
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
Business Today4d
Glaxosmithkline Pharmaceuticals Ltd (GLAXO) Share Price
Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was ...
GSK Nears $1 Billion Deal for Biotech Company IDRx
GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...